AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02461823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia crown
Description: patients will receive a Zirconia crown, the Zirconia crown will cover the natural crown.
Study NCT02461823 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Porcelain metal crown
Description: patients will receive a porcelain fused to metal crown, the Porcelain metal crown will cover the natural crown.
Study NCT04035603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: 50 mg d-cycloserine given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.
Study NCT04035603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: matching 50 mg identical placebo given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.
Study NCT01986556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg (Site 2, Lot B)
Study NCT02500004 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Systemic inflammatory profile: blood sampling.
Study NCT02500004 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Systemic inflammatory profile: blood sampling.
Study NCT02500004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indirect calorimetry
Description: Resting metabolic rate: indirect calorimetry.
Study NCT02500004 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Indirect calorimetry
Description: Resting metabolic rate: indirect calorimetry.
Study NCT02500004 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometry
Description: Physical activity level: accelerometry.
Study NCT02500004 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Accelerometry
Description: Physical activity level: accelerometry.
Study NCT02500004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Double-labeled water
Description: Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.
Study NCT02500004 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Double-labeled water
Description: Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.
Study NCT04959357 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Two dimensional speckle tracking imaging
Description: lobal longitudinal strain and strain rate, subendocardial LS and subepicardial LS were quantified by two dimensional speckle tracking imaging
Study NCT02054182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D 2 500 IU daily from enrolment (within 24 hours of hospitalization) until discharge from hospital
Study NCT02244242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride
Study NCT02720757 — intervention group
Intervention type: DRUG
Intervention: Spiolto Respimat
Description: Tiotropium bromide + Olodaterol
Study NCT00892801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Taken by mouth once a day, for 15 days, one day prior to initiation of whole brain radiation therapy at 5 or 10 mg/day during the phase I component. One of these doses will be selected as the maximum tolerable dose and will be selected for the phase II component
Study NCT00892801 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole-brain radiation therapy
Description: Standard whole brain radiation therapy (WBRT) 30 Gy will be given in ten fractions.
Study NCT04067570 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic body radiation therapy, or SBRT, is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue
Study NCT04881942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product A
Description: e-Vapor product XL25F
Study NCT04929990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training
Description: Inspiratory and expiratory muscle training were performed using a breathing trainer (Dofin DT11/14, Galemed Co. Ltd, Taiwan) for 30 minutes a day with a total of eight weeks. Before the training, the MIP and maximal expiratory pressure (MEP) were documented by the best performance of three trials with a digital pressure gauge (GB60, Jitto International Co. Ltd, Taiwan)
Study NCT04929990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle training
Description: Inspiratory and expiratory muscle training were performed using a breathing trainer (Dofin DT11/14, Galemed Co. Ltd, Taiwan) for 30 minutes a day with a total of eight weeks. Before the training, the MIP and maximal expiratory pressure (MEP) were documented by the best performance of three trials with a digital pressure gauge (GB60, Jitto International Co. Ltd, Taiwan)
Study NCT01099228 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 131-I MIBG and 111-In pentetreotide
Description: Subjects will receive 131I MIBG and 111In pentetreotide(surrogate for Y90-DOTATOC)
Study NCT01099228 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 131-I MIBG and In-111 DOTATATE
Description: 131I MIBG and In-111 DOTATATE (surrogate for 177Lu DOTATATE)
Study NCT01273064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTS-1027
Description: Supplied in 30mg, 10mg, or 5mg tablets (depending on dose arm) taken twice daily for up to 48 weeks.
Study NCT01273064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon
Description: 180 micrograms in 0.5 ml of solution subcutaneously (SQ), delivered in single use syringes administered once per week, for up to 48 weeks.
Study NCT01273064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon
Description: 180 micrograms in 0.5 ml of solution subcutaneously (SQ), delivered in single use syringes administered once per week, for up to 48 weeks.
Study NCT01273064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg capsules of ribavirn taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg
Study NCT01273064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 200 mg capsules of ribavirn taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg
Study NCT01273064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets identical in appearance to CTS-1027 containing inactive ingredients.~Placebo arm patients: Two tablets taken twice daily, for a total daily dose of four tablets.~30 mg CTS-1027 patients: One tablet taken twice daily, for a total daily dose of two tablets. One bottle of placebo is added to the 30mg kits in order to maintain the study blind (all patients recieve two-bottle kits of CTS-1027 and/or placebo).
Study NCT01273064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tablets identical in appearance to CTS-1027 containing inactive ingredients.~Placebo arm patients: Two tablets taken twice daily, for a total daily dose of four tablets.~30 mg CTS-1027 patients: One tablet taken twice daily, for a total daily dose of two tablets. One bottle of placebo is added to the 30mg kits in order to maintain the study blind (all patients recieve two-bottle kits of CTS-1027 and/or placebo).
Study NCT03043833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Wellbeing Course
Description: The Wellbeing Course (Titov et al., 2011) includes five online lessons:~* Lesson 1 presents information on the prevalence of anxiety disorders and depression as well as on how they may interfere with life goals. This lesson also discusses how cognitive, behavioral and physical symptoms can contribute to poor emotional health.~* Lesson 2 presents different strategies to generate realistic cognitions.~* Lesson 3 describes strategies for physical de-arousal and for re-engaging in reinforcing activities.~* Lesson 4 describes avoidance and safety behaviors in relation with anxiety and depression along with graded exposure.~* Lesson 5 is about problem solving, relapse prevention and staying well.~For each lesson, a Do It Yourself guide is included as well vignettes and additional material.
Study NCT04213755 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ROTEM
Description: ROTEM including INTEM, EXTEM, APTEM, and FIBTEM
Study NCT04881942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product B
Description: e-Vapor product XL40CB
Study NCT04773886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral trioxide aggregate
Description: Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent
Study NCT03280979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rescue regimen
Description: In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of TX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.
Study NCT04881942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product C
Description: e-Vapor product XL35WM
Study NCT04881942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product D
Description: e-Vapor product XL40MB
Study NCT01567839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular buccal Infiltration injection
Study NCT02966054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health Physical Activity Intervention Group
Description: Print materials on exercise after cancer, Fitbit Flex for 12 weeks, and daily Text Messages for 12 weeks
Study NCT04855084 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monolithic FDPs: before adjustment
Description: Before the occlusal adjustment, Occlusal relationship recording of the 3-unit monolithic FDPs which was fabricated following the complete digital work-flow.
Study NCT04855084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monolithic FDPs: before adjustment
Description: Before the occlusal adjustment, Occlusal relationship recording of the 3-unit monolithic FDPs which was fabricated following the complete digital work-flow.
Study NCT04855084 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monolithic FDPs: after adjustment
Description: After the occlusal adjustment, Occlusal relationship recording of the 3-unit monolithic FDPs which was fabricated following the complete digital work-flow.
Study NCT04855084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monolithic FDPs: after adjustment
Description: After the occlusal adjustment, Occlusal relationship recording of the 3-unit monolithic FDPs which was fabricated following the complete digital work-flow.
Study NCT04855084 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metal fused porcelain FDPs: before adjustment
Description: Before the occlusal adjustment, Occlusal relationship recording of the 3-unit metal fused porcelain FDPs which was fabricated following the complete conventional manufacturing procedure.
Study NCT04855084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metal fused porcelain FDPs: before adjustment
Description: Before the occlusal adjustment, Occlusal relationship recording of the 3-unit metal fused porcelain FDPs which was fabricated following the complete conventional manufacturing procedure.
Study NCT04855084 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metal fused porcelain FDPs: after adjustment
Description: After the occlusal adjustment, digital occlusal relationship recording was done of the 3-unit metal fused porcelain FDPs which was fabricated following the complete conventional manufacturing procedure.
Study NCT04855084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metal fused porcelain FDPs: after adjustment
Description: After the occlusal adjustment, digital occlusal relationship recording was done of the 3-unit metal fused porcelain FDPs which was fabricated following the complete conventional manufacturing procedure.
Study NCT00947960 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Triheptanoin
Description: 1-2 grams triheptanoin (drug)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months.
Study NCT04035603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open Phase CBT that preceeds the randomization phase
Description: Four sessions of weekly individual cognitive-behavior therapy (CBT: a form of psychotherapy that treats problems by helping people modify thoughts, behaviors, and emotions; in this case, for the goal of smoking cessation). Session topics include educational (e.g., health risks of smoking, effectiveness of different treatment approaches), motivational enhancement (e.g., identifying personally relevant benefits of quitting, and costs of continuing to smoke), and cognitive-behavioral elements (e.g., identifying smoking triggers, developing coping strategies for these triggers, planning for high risk situations, relapse prevention).
Study NCT04035603 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Open Phase CBT that preceeds the randomization phase
Description: Four sessions of weekly individual cognitive-behavior therapy (CBT: a form of psychotherapy that treats problems by helping people modify thoughts, behaviors, and emotions; in this case, for the goal of smoking cessation). Session topics include educational (e.g., health risks of smoking, effectiveness of different treatment approaches), motivational enhancement (e.g., identifying personally relevant benefits of quitting, and costs of continuing to smoke), and cognitive-behavioral elements (e.g., identifying smoking triggers, developing coping strategies for these triggers, planning for high risk situations, relapse prevention).
Study NCT04035603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open phase smoking cessation pharmacotherapy that proceeds the randomization phase
Description: Initiating 2 weeks prior to quit date and continuing for 8 weeks after quit date, choice of one of three pharmacological smoking cessation aids: Nicotine Replacement Therapy (nicotine patch), Varenicline, or Bupropion.
Study NCT04035603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Open phase smoking cessation pharmacotherapy that proceeds the randomization phase
Description: Initiating 2 weeks prior to quit date and continuing for 8 weeks after quit date, choice of one of three pharmacological smoking cessation aids: Nicotine Replacement Therapy (nicotine patch), Varenicline, or Bupropion.
Study NCT04104633 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood samples
Description: 30 ml of blood collection
Study NCT00947960 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vegetable Oil
Description: 1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 g triheptanoin (drug)/kilogram body weight for 6 months.
Study NCT01149629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droxidopa
Description: One capsule containing 300 mg droxidopa, given once
Study NCT01149629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droxidopa
Description: 3 capsules each containing 100 mg droxidopa, give 3 times at 4 hour intervals
Study NCT01149629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droxidopa
Description: 3 capsules each containing 100 mg droxidopa, given once
Study NCT03967730 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sonodynamic therapy(SDT)
Description: Sonodynamic Therapy (SDT) Sinoporphyrin Sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection(0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15 min of each lesion. Ultrasound parameters included intensity of 2.1W/cm2 for each lesion, resonance frequency: 1.0 MHz and duty factor: 30%.
Study NCT01491880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-Assisted by Telephone
Description: Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
Study NCT01491880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Help
Description: Parents will receive educational workbooks to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries independently. Parents will have the option to access support over the phone from a child anxiety specialist.
Study NCT01636609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study NCT01636609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given SC
Study NCT01636609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tosedostat
Description: Given PO
Study NCT03280979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose methotrxate
Description: In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid
Study NCT00584870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Oral naproxen 500 mg twice daily for Weeks 1-12.
Study NCT00584870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV infusion of placebo on Day 1 and placebo for naproxen twice daily for Weeks 1-12.
Study NCT00584870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04383119 (RN624)
Description: Single IV infusion of 200 micrograms/kg RN624 on Day 1
Study NCT01239355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO
Study NCT01239355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT05343637 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
Description: RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.
Study NCT01063556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil HCl
Description: Subjects will receive donepezil HCL 3 mg without haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg with haemodialysis.
Study NCT01063556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil HCl
Description: Subjects will receive donepezil HCl 3 mg with haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg without haemodialysis.
Study NCT04395677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-106
Description: Stage 1: 400mg QD for 3 patients and 600mg QD for 3 patients~Stage 2: 600mg QD
Study NCT03536884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.
Study NCT03536884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.
Study NCT03536884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Subjects will receive secukinumab at pre-specified time-points.
Study NCT03536884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time-points to maintain the blinding in the double-blind Treatment Period.
Study NCT02323880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02323880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study NCT02548637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture Therapy
Description: The standard textbook of Chinese Acupuncture and Moxibustion is the source for the name and location of the points for this study. A total of 38 points will be used, divided between two acupuncture sessions: 20 points or 37 locations in the supine position; 18 points or 36 locations in the prone position. Other than points governing vessel (GV) 20, conception vessel (CV) 6, CV 10, all points will be performed bilaterally.
Study NCT02135380 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Autologous Stromal Vascular Fraction (SVF)
Description: Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously.
Study NCT02135380 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Autologous Adipose Derived MSCs (ADMSCs)
Description: Study arm B subjects will receive total 3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each. All the three doses will be given at weekly intervals.